+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Treprostinil"

TYVASO Drug Insight and Market Forecast - 2032 - Product Thumbnail Image

TYVASO Drug Insight and Market Forecast - 2032

  • Drug Pipelines
  • December 2022
  • 30 Pages
  • Global
From
From
From
From
From
Disease Analysis: Pulmonary Hypertension - Product Thumbnail Image

Disease Analysis: Pulmonary Hypertension

  • Drug Pipelines
  • April 2021
  • 78 Pages
  • Global
Tyvaso - Product Thumbnail Image

Tyvaso

  • Report
  • October 2018
  • 17 Pages
  • Global
From
From
From
From
From
From
From
From
From
From
From
Loading Indicator

Treprostinil is a drug used to treat respiratory diseases such as pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH). It is a prostacyclin analogue, meaning it works by mimicking the effects of prostacyclin, a naturally occurring hormone in the body that helps to regulate blood pressure in the lungs. Treprostinil is administered through a variety of methods, including oral tablets, subcutaneous injections, and inhalation. It is also available in a topical form for the treatment of Raynaud's phenomenon. Treprostinil is a relatively new drug, having been approved by the FDA in 2002. It is used to treat a variety of respiratory diseases, including PAH, CTEPH, and Raynaud's phenomenon. It is also used to treat other conditions such as sickle cell anemia and cystic fibrosis. The treprostinil market is a growing one, with many companies offering products and services related to the drug. Some of these companies include United Therapeutics, Actelion Pharmaceuticals, GlaxoSmithKline, and Pfizer. Show Less Read more